AZ Goes Into The MYSTIC And Finds Positives For Imfinzi
Against all the odds, AstraZeneca still has hopes for Imfinzi in first-line NSCLC with data from the failed MYSTIC trial suggesting strong survival in patients with a high tumour mutation burden.
You may also be interested in...
The drug major has presented a set of financials that have comfortably surpassed analyst forecasts and show that its new oncology therapies now make up around 30% of group sales and are growing strongly.
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
The latest failure of the combination of AZ's PD-L1 inhibitor and its CLTA4 inhibitor is in advanced head and neck cancer. It follows recent failures of the MYSTIC and ARCTIC trials in lung cancer.